hallucinations – Page 2

Psychedelics action and schizophrenia

mycolabadmin

This review examines how psychedelic drugs like psilocybin and LSD affect the brain, particularly through serotonin receptors. While these compounds can produce psychosis-like symptoms similar to schizophrenia, they also promote brain plasticity and growth of neural connections. The article discusses whether psychedelics could potentially treat negative symptoms and cognitive problems in schizophrenia patients, despite their mind-altering properties, possibly through lower doses or non-hallucinogenic alternatives.

Current situation regarding psychedelics and magic mushroom in Korea

mycolabadmin

This article reviews the current status of psychedelic mushrooms and their potential medical uses in Korea. Several wild mushroom species containing psilocybin have been identified in Korea and can cause hallucinations and other nervous system effects lasting a few hours. While psychedelics show promise for treating depression and anxiety, Korea currently classifies them as controlled substances, and only approved clinical trials can be conducted with government permission.

New and emerging pharmacologic treatments for MDD

mycolabadmin

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

Psychedelic-assisted psychotherapy: The need to monitor adverse events

mycolabadmin

While psychedelics show promise for treating depression and other mental health conditions, researchers need better systems to monitor and report any harmful effects they might cause. This paper calls for more careful, consistent tracking of both physical changes (like blood pressure) and psychological experiences during psychedelic therapy. The authors emphasize that safety monitoring should continue even after patients leave the clinic and that women may experience different side effects than men.

The psychedelic-peptide paradox: a hormetic hypothesis

mycolabadmin

This review explores how psychedelic drugs like LSD and psilocybin work through the body’s natural stress-response systems, particularly two brain chemicals called oxytocin and vasopressin. It explains why psychedelics initially cause uncomfortable feelings like nausea and anxiety, but these are followed by improved mood, sociability, and emotional healing. The theory suggests that this initial ‘stress’ response triggers the body’s natural healing mechanisms, similar to how physical exercise makes you uncomfortable initially but builds strength over time.

Neurotoxicity associated with the medicinal mushroom product-Diamond Shruumz: A case report

mycolabadmin

A 17-year-old girl became severely ill after eating a chocolate bar containing a medicinal mushroom product that was contaminated with muscimol, a toxic compound from poisonous mushrooms. She experienced confusion, uncontrollable muscle jerks, dilated pupils, and excessive drooling, requiring hospitalization and temporary breathing assistance. Though her symptoms resolved within 8 hours and she recovered fully, this case highlights the serious danger of unregulated mushroom supplements that can be contaminated with deadly toxins.

Successful management of Lomentospora prolificans septic arthritis and osteomyelitis in an immunocompetent child: A case report

mycolabadmin

A 3-year-old boy developed a serious fungal bone and joint infection caused by Lomentospora prolificans after surgery to fix a broken elbow. This fungus is extremely resistant to most antifungal medications. The infection was successfully treated using multiple approaches: aggressive surgical cleaning, several different antifungal drugs used together, special antibiotic-loaded bone cement, and antiseptic rinses. After two months of intensive treatment, the infection cleared and the child’s arm was saved from amputation.

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

mycolabadmin

This review examines how psychedelic drugs like LSD and psilocybin might help treat chronic pain conditions such as cluster headaches and phantom limb pain. The researchers found nine studies suggesting these substances could reduce pain by affecting serotonin receptors in the brain. While early results are promising, more rigorous clinical trials are needed before these drugs can become standard pain treatments. The authors note that strict legal restrictions on psychedelics currently limit research opportunities.

Anti-Therapeutic Action: hallucinations